Donner Daniel G, Beck Belinda R, Bulmer Andrew C, Lam Alfred K, Du Toit Eugene F
Heart Foundation Research Centre, Griffith Health Institute, Griffith University, Gold Coast, Queensland, Australia.
School of Allied Health Sciences, Griffith University, Gold Coast, Queensland, Australia.
Steroids. 2015 Feb;94:60-9. doi: 10.1016/j.steroids.2014.12.017. Epub 2014 Dec 30.
Trenbolone (TREN) is used for anabolic growth-promotion in over 20 million cattle annually and continues to be misused for aesthetic purposes in humans. The current study investigated TREN's effects on body composition and cardiometabolic risk factors; and its tissue-selective effects on the cardiovascular system, liver and prostate. Male rats (n=12) were implanted with osmotic infusion pumps delivering either cyclodextrin vehicle (CTRL) or 2mg/kg/day TREN for 6 weeks. Dual-energy X-ray Absorptiometry assessment of body composition; organ wet weights and serum lipid profiles; and insulin sensitivity were assessed. Cardiac ultrasound examinations were performed before in vivo studies assessed myocardial susceptibility to ischemia-reperfusion (I/R) injury. Circulating sex hormones and liver enzyme activities; and prostate and liver histology were examined. In 6 weeks, fat mass increased by 34±7% in CTRLs (p<0.01). Fat mass decreased by 37±6% and lean mass increased by 11±4% with TREN (p<0.05). Serum triglycerides, HDL and LDL were reduced by 62%, 57% and 78% (p<0.05) respectively in TREN rats. Histological examination of the prostates from TREN-treated rats indicated benign hyperplasia associated with an increased prostate mass (149% compared to CTRLs, p<0.01). No evidence of adverse cardiac or hepatic effects was observed. In conclusion, improvements in body composition, lipid profile and insulin sensitivity (key risk factors for cardiometabolic disease) were achieved with six-week TREN treatment without evidence of adverse cardiovascular or hepatic effects that are commonly associated with traditional anabolic steroid misuse. Sex hormone suppression and benign prostate hyperplasia were confirmed as adverse effects of the treatment.
群勃龙（TREN）每年用于超过2000万头牛的合成代谢促生长，并且仍被滥用于人类的美容目的。本研究调查了群勃龙对身体成分和心脏代谢危险因素的影响；以及其对心血管系统、肝脏和前列腺的组织选择性作用。雄性大鼠（n = 12）植入渗透式输液泵，持续6周给予环糊精载体（CTRL）或2mg/kg/天的群勃龙。通过双能X线吸收法评估身体成分；测量器官湿重和血清脂质谱；并评估胰岛素敏感性。在体内研究评估心肌对缺血再灌注（I/R）损伤的易感性之前，进行心脏超声检查。检测循环性激素和肝酶活性；并检查前列腺和肝脏组织学。6周后，CTRL组的脂肪量增加了34±7%（p<0.01）。使用群勃龙后，脂肪量减少了37±6%，瘦体重增加了11±4%（p<0.05）。群勃龙处理的大鼠血清甘油三酯、高密度脂蛋白和低密度脂蛋白分别降低了62%、57%和78%（p<0.05）。对群勃龙处理的大鼠前列腺进行组织学检查，结果显示良性增生伴前列腺重量增加（与CTRL组相比增加149%，p<0.01）。未观察到心脏或肝脏有不良影响的证据。总之，六周的群勃龙治疗改善了身体成分、血脂谱和胰岛素敏感性（心脏代谢疾病的关键危险因素），且没有传统合成代谢类固醇滥用常见的不良心血管或肝脏影响的证据。性激素抑制和良性前列腺增生被确认为该治疗的不良反应。
